# A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

> **NCT02000934** · PHASE1 · COMPLETED · sponsor: **Calithera Biosciences, Inc** · enrollment: 143 (actual)

## Conditions studied

- Advanced Solid Tumor and Lymphoma Malignancies

## Interventions

- **DRUG:** TAK-659

## Key facts

- **NCT ID:** NCT02000934
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-31
- **Primary completion:** 2021-06-29
- **Final completion:** 2021-06-29
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02000934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02000934, "A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02000934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*